# Emily Leproust

> Emily Leproust is a seed investor at NFX Bio backing Biotechnology. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [NFX Bio](https://shizune.co/investors/profile/nfx-bio)
- Location: San Francisco, United States
- Total investments: 3
- Last investment: Jul 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/emily-leproust/
- X (Twitter): http://twitter.com/EmilyLeproust
- Website: https://x.com/EmilyLeproust
- Facebook: https://www.facebook.com/emily.leproust

Emily Leproust is a seed investor at NFX Bio in San Francisco focused on Biotechnology and Health Care. As an early pioneer in long DNA synthesis, Emily is poised to accelerate the biofactory market. She and co-founder Bill Peck share the world record for synthesizing the longest, highest quality oligo library. Emily architected the successful SureSelect product line which lowered the cost of sequencing and elucidated dozens of mendelian diseases,and she developed Agilent’s Oligo Library Synthesis technology. Emily has co-authored over 34 peer-reviewed papers—many on synthetic DNA—and has extensive marketing, management, and business development experience. Prior to Twist Bioscience, Emily was Director of Applications and Chemistry R&D—Genomics at Agilent Technologies.

## Contacts

5 contacts available for Emily Leproust: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/dr-emily-leproust?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.5M–$5.7M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Health Care | 2 | 67% |
| Product Research | 1 | 33% |
| Food and Beverage | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Switzerland | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biostate AI | Biostate AI develops generative AI that benefit all human health. | $4M | Seed | Jul 08, 2024 |  |
| Cradle | Using robust prediction algorithms and AI design recommendations, Cradle assists biologists in rapidly designing better proteins. Cradle gives you complete ownership of the intellectual property while maintaining the privacy and security of your sequences and data. | $5.7M | Seed | Nov 16, 2022 |  |
| Kiwi Biosciences | Kiwi biosciences is a biotech company that develops enzymes to make food for patients who suffer from Irritable Bowel Syndrome (IBS). The company was founded in 2020 and is based in Somerville, Massachusetts, United States. | $1.5M | Seed | Oct 14, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Acacia Venture Capital Partners](https://shizune.co/investors/profile/acacia-venture-capital-partners) — VC Fund, 1 deal together
- [Caltech](https://shizune.co/investors/profile/caltech) — VC Fund, 1 deal together
- [Catapult Ventures](https://shizune.co/investors/profile/catapult-ventures) — VC Fund, 1 deal together
- [Index Ventures](https://shizune.co/investors/profile/index-ventures) — VC Fund, 1 deal together
- [Kindred Capital](https://shizune.co/investors/profile/kindredcapital) — VC Fund, 1 deal together
- [Matter Venture Partners](https://shizune.co/investors/profile/matter-venture-partners) — VC Fund, 1 deal together

## About NFX Bio

VC Fund · San Francisco, United States

NFX Bio is a fund initiative that seeks to invest in scientist-founders at the seed stage with a technology platform approach.Led by Omri Amirav Drory, a venture partner with NFX, who founded Genome Compiler, it helps scientists learn to be founders and guides biology companies with information technology to be a critical distinction with massiveimplications.

5 contacts available at NFX Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Emily Leproust | Investment Committee | https://shizune.co/investors/profile/dr-emily-leproust |
| Gigi Levy Weiss | Investment Committee | https://shizune.co/investors/profile/gigi-levy-weiss |
| Gita Reinitz | Principal | https://shizune.co/investors/profile/gita-reinitz |
| James Currier | Investment Committee | https://shizune.co/investors/profile/james-currier |
| Omri Amirav-Drory | Venture Partner | https://shizune.co/investors/profile/omri-amirav-drory |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Biotechnology Angel Investors in Switzerland](https://shizune.co/investors/biotechnology-angel-investors-switzerland)
- [Biotech Angel Investors in Switzerland](https://shizune.co/investors/biotech-angel-investors-switzerland)
- [Enterprise Angel Investors in Switzerland](https://shizune.co/investors/enterprise-angel-investors-switzerland)

## FAQ

### What does Emily Leproust invest in?

Emily Leproust invests primarily in Biotechnology, Health Care and Product Research startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Emily Leproust's check size?

Emily Leproust typically joins rounds of $1.5M–$5.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Emily Leproust participates in.

### How do I contact Emily Leproust?

Public channels for Emily Leproust include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Emily Leproust last invest?

The most recent investment recorded for Emily Leproust closed in Jul 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co